Karolinska University Hospital — Sponsor Intelligence | 58 EU Trials

Filter these 58 trials by condition, phase, country and more.

Open in Search →

58 Registered trials

31 Recruiting

13 Completed trials

18 Countries active

105 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I (Other)

Phase III: 12 Phase II/III: 2 Phase II: 26 Phase I/II: 2 Phase III/IV: 2 Phase IV: 6 Phase I: 1 Phase I (Other): 6 Other: 1

Oversight events:

3 serious breaches 6 temporary halts across 2 trials

View oversight register →

100%

13 of 13 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 2 Follicular lymphoma 1 Malignant melanoma stage III 1 Ovarian cancer 1 Rheumatoid arthritis 1 Thyroid cancer stage IV 1 Anaplastic thyroid cancer 1 Breast cancer stage II 1 Eastern Cooperative Oncology Group performance status 1 Hyperthyroidism 1 Prostate cancer recurrent 1 Squamous cell carcinoma of the vulva 1

Top IMPs

PACLITAXEL 3 PREDNISOLONE 3 CARBOPLATIN 2 CYTARABINE 2 DEXAMETHASONE 2 DOCETAXEL 2 GALLIUM (68GA) TEZATABEP MATRAXETAN 2 LETROZOLE 2 METHOTREXATE 2 NIVOLUMAB 2 PERTUZUMAB 2 SEMAGLUTIDE 2

All trials — page 2

58 total

Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1… Recruiting

2023-508196-36-00 Phase II 5 countries TAFASITAMAB
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and it… Recruiting

2023-508126-95-00 Phase I 1 country
Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION) Recruiting

2023-505990-34-00 Phase II 1 country CYTARABINE; DEXAMETHASONE; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB
Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcuta… Recruiting

2023-510184-35-00 Phase IV 5 countries ADALIMUMAB
Preoperative Lugol’s solution in Graves’ disease and toxic nodular goiter Recruiting

2024-517110-15-00 Phase III 1 country
FAPI-PET imaging in solid tumors Recruiting

2024-514967-25-00 Phase II 2 countries (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
MethMax trial Recruiting

2023-507714-27-00 Phase IV 6 countries METHOTREXATE
PARACHUTES: Pedophilia At Risk – Acute Treatment – E-therapy vs SSRI Recruiting

2024-513388-16-00 Phase II 1 country
Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled pha… Recruiting

2023-504278-39-00 Phase II 1 country BENSERAZIDE HYDROCHLORIDE, LEVODOPA; MONTELUKAST SODIUM
LiBRA – Lithium treatment to prevent cognitive impairment after brain radiotherapy. Recruiting

2023-504071-24-00 Phase II 2 countries LITHIUM SULPHATE, ANHYDROUS
CITAR - Comparison of the efficacy and safety of early use of IL-6R blockade with tocilizumab in combination with short-term glucocorticoids… Recruiting

2022-501130-33-00 Phase II 2 countries PREDNISOLONE; TOCILIZUMAB
PARP-PET in solid tumors Recruiting

2022-502918-87-00 Phase I (Other) 1 country
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting

2022-501504-95-00 Phase II 3 countries APREPITANT; BETAMETHASONE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAX…
Observational Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Patients with Chronic hepatitis D Recruiting

2023-504414-29-00 Phase III/IV 1 country BULEVIRTIDE; ENTECAVIR; PEGINTERFERON ALFA-2A; TENOFOVIR ALAFENAMIDE; TENOFOVIR …
SACK Recruiting

2022-501600-10-00 Phase III 7 countries APIXABAN
Utvärdering av två kortison behandlingsstrategier hos patienter med nydiagnostiserad, tidigare obehandlad reumatoid artrit: en randomiserad,… Recruiting

2024-518775-54-00 Phase IV 1 country PREDNISOLONE
NMDSG-14B2 Recruiting

2024-511651-17-00 Phase II 4 countries
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting

2022-501050-11-01 Phase II/III 14 countries BLINATUMOMAB; INOTUZUMAB OZOGAMICIN; TIOGUANINE
PiSCATIN - Simvastatin for the treatment of primary sclerosing cholangitis (PSC) - a randomized double-blind, placebo-controlled multicenter… Recruiting

2024-511053-22-00 Phase II 1 country SIMVASTATIN
A study to compare conventional "salvage" radiotherapy and individualized treatment based on results from PSMA PET/CT assessments in patient… Recruiting

2023-504917-54-00 Phase III 1 country (3S,10S,14S)-1-[4-[[(2S)-4-CARBOXY-2-[(2S)-4-CARBOXY-2-(6-[18F] FLUOROPYRIDIN-3-…
Desferal administration to improve the impaired reaction to hypoxia in diabetes (DESIRED) - A randomised, double-blind, placebo-controlled, … Recruiting

2024-519562-48-00 Phase II 1 country DEFEROXAMINE MESILATE
A phase II trial of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma LuDO-N Ended

2023-503684-42-00 Phase II 6 countries EDOTREOTIDE; L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) …
Intralymfatisk immunterapi förstärkt av vitamin-D, en randomiserad placebokontrollerad studie och jämförelse med SLIT Ended

2024-515271-35-00 Phase II/III 1 country PHLEUM PRATENSE (225); SODIUM CHLORIDE
[68Ga]Ga-ABY-025 PET in solid tumors Ended

2022-500448-39-00 Phase II 1 country GALLIUM (68GA) TEZATABEP MATRAXETAN

Showing 25–48 of 58 trials

← All sponsors A–Z